The Effect of AUDIT and Feedback on Pneumococcal Vaccination Coverage

Launched by BERT VAES · Jun 17, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how "Audit and Feedback" can improve the rates of pneumococcal vaccinations among adults who are at risk of pneumonia. The goal is to see if providing information and feedback to doctors about their vaccination practices can help more patients get vaccinated. The trial will involve general practice centers that will either receive regular feedback about their vaccination efforts or not, allowing researchers to compare the outcomes between the two groups. They will also look at whether certain groups, like men and women, younger and older adults, or smokers, benefit more from the feedback.

To participate in the trial, general practice centers must be part of a specific network and use an electronic health record system. Eligible patients include adults aged 16 to 85 who have a high risk for pneumococcal infections, such as those with certain medical conditions or those aged 65 and older. Participants can expect their doctors to receive helpful reports every two months to encourage better vaccination practices. This study aims to make sure that more people at risk are protected against pneumonia.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• * To be eligible for inclusion in the study, general practice (GP) centers must conform to the following conditions:
• • 1. It is a Flemish GP center in the INTEGO network.
• • 2. The GP center uses an electronic health record (EHR), automatically linked to the INTEGO database.
• • 3. The physician (one per center, in name of all GPs in that center) signs a specific study consent form.
• * To be eligible for inclusion in the study, patients must conform to the following conditions:
• 1. The patient belongs to a target group for pneumococcal vaccination (based on https://www.health.belgium.be/sites/default/files/uploads/fields/fpshealth_theme_file/hgr_9562_vaccinatie_tegen_pneumokokken_vweb.pdf):
• • A. Adults aged 16 - 85 years old with a high risk for a pneumococcal infection
• • Adults with an immunity disorder
• • Adults with anatomical and / or functional asplenia, sickle-cell disease or hemoglobinopathy
• • Adults with cerebrospinal fluid or cochlear implant leakage B. Adults (aged 50 - 85 years old) with comorbidity
• • Chronic cardiac disease
• • Chronic pulmonary disease or smoker
• • Chronic liver disease or ethylabusus
• • Chronic kidney disease
• • Chronic neurological or neuromuscular disorders with aspiration risk
• • Diabetes mellitus C. Healthy persons aged 65 - 85 years old
• • 2. The patient has an electronic medical record (EMR) in the participating general practice centre. This EMR contains all the patient information, for instance regarding medical history and medication and is managed by the general practitioner.
• • Exclusion criteria
• • Patients excluded from feedback: patients not belonging to one of the target groups for pneumococcal vaccination.
• • Patients excluded from AUDIT: patients not belonging to one of the target groups for pneumococcal vaccination OR
• • Correctly vaccinated high-risk patients (PPV23 less than 5 years ago AND PCV13 ever received)
• • Correctly vaccinated adults with comorbidity (1) PCV13 ever received AND PPV23 less than 5 years ago, OR 2) PCV13 ever received AND 2x PPV23 vaccination more than 5 years ago)
• • Correctly vaccinated healthy persons (PPV23 ever received)